

- B2  
concl'd.
- b) transplanting the donor cells, tissue or organ, into the recipient, such that a rejection response by the recipient to the donor cells, tissue or organ, is inhibited.

Please amend claim 22 as follows:

- B3  
SVB  
C 4
22. The method of claim 1, wherein the immunosuppressant is administered beginning from about 0 to 6 hours before the transplanting step [and continuing for up to several weeks after the transplant step].--
- Po AB

REMARKS

Original claims 11-21 and 23-25 are canceled herein without prejudice, and claims 1 and 22 are amended. The specification is amended herein to claim priority to a previously filed application. The amended claims incorporate some amendments made in the parent application and additionally provide that the anti-CD3-DT immunotoxin used in the claimed method comprises sFv-DT390. Support for the immunotoxin comprising sFv-DT390 can be found in the specification in Example 9. No new matter is believed to be added by these amendments.

The Examiner is invited and encouraged to directly contact the undersigned if such contact may enhance the efficient prosecution of this application to issue. No fees are believed to

ATTORNEY DOCKET NO. 14028.0292  
SERIAL NO. Unassigned

be due. However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.



Gwendolyn D. Spratt  
Registration No. 36,016

NEEDLE & ROSENBERG, P.C.  
Suite 1200, The Candler Building  
127 Peachtree Street, N.E.  
Atlanta, Georgia 30303-1811  
404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EL348125507US in an envelope addressed to: BOX PATENT APPLICATION Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

  
Kevin Lightburn

26 Aug '99  
Date